Tag: Factor viii

The duration of a factor VIII infusion varies significantly based on the product, with conventional standard half-life (SHL) concentrates lasting approximately 8 to 12 hours in adults due to their relatively short circulating half-life. This differs considerably from newer extended half-life (EHL) treatments, which are engineered to remain active for longer periods and reduce the frequency of infusions.

Hemophilia A, an inherited bleeding disorder, affects approximately one in 5,000 male births worldwide. The primary and most effective treatment for this condition is the replacement of the missing or deficient clotting protein, which is known as **what is factor 8 used to treat**.

In clinical trials, a single infusion of valoctocogene roxaparvovec reduced the mean annualized bleeding rate by 83.8% compared to prior Factor VIII prophylaxis [1.10.3]. This one-time gene therapy is transforming treatment, but how is valoctocogene roxaparvovec administered to achieve such significant results?

According to clinical trial data, valoctocogene roxaparvovec (brand name Roctavian) demonstrated a significant reduction in annualized bleeding rates for men with severe hemophilia A. This innovative treatment represents a major advancement in the management of this genetic bleeding disorder by addressing its root cause through gene therapy.

Hemophilia A is a genetic bleeding disorder that affects approximately 1 in 5,000 male births and is caused by a deficiency of clotting factor VIII. The medication **Kogenate**, a brand of recombinant Factor VIII, works by temporarily replacing this missing protein, restoring the blood's ability to clot effectively and enabling the control and prevention of bleeds.